Home
Series of Journals
Literature
Latest literature
Popular literature
About us
Intro
Organizational structure
Editor in Chief
Copyright
Contact us
The title
The title
The keywords
The author
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University
Home
Results
The title
The title
The keywords
The author
A total of
7
result was found. Results that relate to
Cost-utility analysis
Pharmacoeconomic evaluation of Huangkui capsule versus losartan potassium tablets in the treatment of IgA nephropathy
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(1):02-09.
2982 times
2061 times
Liang-Wen GOU
Zhao-Ting GUO
Qiong LUO
Nan YANG
Ming HU
Huangkui capsule
Losartan potassium tablets
Chronic kidney disease
Pharmacoeconomics
Cost-utility analysis
Details
Cost-utility analysis of Shenling Baizhu powder in treatment of sarcopenia in older men
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(4):376-383.
959 times
318 times
Huan-Huan JIANG
Hui-Qin SHEN
Zhi-Xiu WANG
Yun-Fei CHEN
Hui GUO
Na XU
Shenling Baizhu powder
Sarcopenia
Cost-utility analysis
Pharmacoeco-nomics
Details
Cost-utility analysis of sacubitril/valsartan, dapagliflozin and empagliflozin in heart failure with reduced ejection fraction
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(8):878-885.
665 times
271 times
Dan-Dan LU
Sheng-Xiang WANG
Shan LU
Dan PAN
Li-Yuan SHI
Fei-Chuang Jing2
Heart failure with reduced ejection fraction
Sacubitril/valsartan
Dapagliflozin
Empagliflozin
Markov model
Cost-utility analysis
Details
Cost-utility analysis of budesonide/formoterol powder inhalation versus salmeterol/fluticasone powder inhalation for asthma in adolescents
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(1):60-67.
610 times
417 times
SHEN Anle
WU Bin
LIU Dan
JIANG Yuelian
WU Juan
YIN Yong
ZHANG Shunguo
Budesonide/formoterol
Salmeterol/fluticasone
Cost-utility analysis
Asthma
Adolescent
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(12):1371-1379.
476 times
224 times
La-Ji DANZENG
Yong-Gong YANG
Si-Liang WANG
Meng-Ying LIU
Azacitidine
Decitabine
Myelodysplastic syndrome
Markov model
Cost-utility analysis
Pharmacoeconomics
Details
Pharmacoeconomic evaluation of different doses of rivaroxaban for the prevention of thrombosis in patients with nonvalvular atrial fibrillation
Published on
China Pharmacist
2023,36(11):233-240.
442 times
283 times
Wei LUO
Xue-Ying PENG
Dong YANG
Xin-Mei WU
Nonvalvular atrial fibrillation
Rivaroxaban
Dose selection
Markov model
Cost-utility analysis
Details
Cost-utility analysis of edaravone dexborneol for acute ischemic stroke
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(1):68-74.
485 times
1371 times
ZHOU Shasha
CHEN Xiangfan
CHEN Xia
Edaravone dexborneol
Edaravone
Acute ischemic stroke
Decision tree model
Cost-utility analysis
Details